,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': 'As part of the 2013 consultation on the amendment of access to lamivudine, PHARMAC staff received a request to consider access to lamivudine for patients who are hepatitis B surface antigen (HBsAg) negative/ hepatitis B core antibody (anti-HBc) positive patients who are receiving rituximab in the absence of high dose steroid (anti-HBc + patients who are receiving rituximab in combination with high dose steroid are already eligible for funded lamivudine treatment).', 'fs': 'As part of the 2013 consultation on the amendment of access to lamivudine, PHARMAC staff received a request to consider access to lamivudine for patients who are hepatitis B surface antigen (HBsAg) negative/ hepatitis B core antibody (anti-HBc) positive patients who are receiving rituximab in the absence of high dose steroid (anti-HBc + patients who are receiving rituximab in combination with high dose steroid are already eligible for funded lamivudine treatment).', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2013', 'fs': 'Apr 2013', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAJyUAO'}, 'Id': 'a0P2P000005PAJyUAO', 'Event_Date__c': '2013-04-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'As part of the 2013 consultation on the amendment of access to lamivudine, PHARMAC staff received a request to consider access to lamivudine for patients who are hepatitis B surface antigen (HBsAg) negative/ hepatitis B core antibody (anti-HBc) positive patients who are receiving rituximab in the absence of high dose steroid (anti-HBc + patients who are receiving rituximab in combination with high dose steroid are already eligible for funded lamivudine treatment).', 'Formatted_Date__c': 'Apr 2013', 'Status_History__c': 'a132P000000AqNCQA0'}, 'change': None}]",Apr 2013,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'PHARMAC staff referred the request to the Anti-infective Subcommittee of PHARMAC', 'fs': 'PHARMAC staff referred the request to the Anti-infective Subcommittee of PHARMAC', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAJzUAO'}, 'Id': 'a0P2P000005PAJzUAO', 'Event_Date__c': '2013-05-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': 'PHARMAC staff referred the request to the Anti-infective Subcommittee of PHARMAC', 'Formatted_Date__c': 'May 2013', 'Status_History__c': 'a132P000000AqO7QAK'}, 'change': None}, {'Summary': {'s': 'The Anti-infective subcommittee considered that the risk of hepatitis B reactivation in patients who are  HBsAg negative, anti-HBcore positive was because of the specific effect of anti-CD20 on humoral immunity combined with high dose steroids, which have a specific direct effect on hepatitis B virus replication through activation of the glucocorticoid-responsive element on the hepatitis B virus  genome.  In situations where a high dose steroid is not being used, prophylaxis was not considered necessary.', 'fs': 'The Anti-infective subcommittee considered that the risk of hepatitis B reactivation in patients who are  HBsAg negative, anti-HBcore positive was because of the specific effect of anti-CD20 on humoral immunity combined with high dose steroids, which have a specific direct effect on hepatitis B virus replication through activation of the glucocorticoid-responsive element on the hepatitis B virus  genome.  In situations where a high dose steroid is not being used, prophylaxis was not considered necessary.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-02.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-02.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2014', 'fs': 'Feb 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 26 February 2014.', 'fs': 'Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 26 February 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK0UAO'}, 'Id': 'a0P2P000005PAK0UAO', 'Event_Date__c': '2014-02-26', 'Event_Description__c': 'Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 26 February 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-02.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Anti-infective subcommittee considered that the risk of hepatitis B reactivation in patients who are  HBsAg negative, anti-HBcore positive was because of the specific effect of anti-CD20 on humoral immunity combined with high dose steroids, which have a specific direct effect on hepatitis B virus replication through activation of the glucocorticoid-responsive element on the hepatitis B virus  genome.  In situations where a high dose steroid is not being used, prophylaxis was not considered necessary.', 'Formatted_Date__c': 'Feb 2014', 'Status_History__c': 'a132P000000Aqc3QAC'}, 'change': None}, {'Summary': {'s': 'PHARMAC received further information for the application for funding of lamivudine prophylaxis for hepatitis B surface antigen (HBsAg) negative/ hepatitis B core antibody (anti-HBc) positive patients who are receiving rituximab in the absence of high dose steroid (anti-HBc + patients who are receiving rituximab in combination with high dose steroid are already eligible for funded lamivudine treatment).', 'fs': 'PHARMAC received further information for the application for funding of lamivudine prophylaxis for hepatitis B surface antigen (HBsAg) negative/ hepatitis B core antibody (anti-HBc) positive patients who are receiving rituximab in the absence of high dose steroid (anti-HBc + patients who are receiving rituximab in combination with high dose steroid are already eligible for funded lamivudine treatment).', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2015', 'fs': 'Jan 2015', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK1UAO'}, 'Id': 'a0P2P000005PAK1UAO', 'Event_Date__c': '2015-01-16', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': 'PHARMAC received further information for the application for funding of lamivudine prophylaxis for hepatitis B surface antigen (HBsAg) negative/ hepatitis B core antibody (anti-HBc) positive patients who are receiving rituximab in the absence of high dose steroid (anti-HBc + patients who are receiving rituximab in combination with high dose steroid are already eligible for funded lamivudine treatment).', 'Formatted_Date__c': 'Jan 2015', 'Status_History__c': 'a132P000000Aqr7QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2015', 'fs': 'Nov 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK2UAO'}, 'Id': 'a0P2P000005PAK2UAO', 'Event_Date__c': '2015-11-04', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2015', 'Status_History__c': 'a132P000000Ar0sQAC'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that lamivudine be funded for hepatitis B (HBV) reactivation prophylaxis for immunocompromised patients with a high priority. The Subcommittee recommended that &#39;immunocompromised&#39; be defined as &#39;any malignancy receiving rituximab and other immunosuppressant chemotherapies&#39;.', 'fs': 'The Subcommittee recommended that lamivudine be funded for hepatitis B (HBV) reactivation prophylaxis for immunocompromised patients with a high priority. The Subcommittee recommended that &#39;immunocompromised&#39; be defined as &#39;any malignancy receiving rituximab and other immunosuppressant chemotherapies&#39;.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2015-11.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2015-11.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2015', 'fs': 'Nov 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 4 November 2015.', 'fs': 'Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 4 November 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK3UAO'}, 'Id': 'a0P2P000005PAK3UAO', 'Event_Date__c': '2015-11-04', 'Event_Description__c': 'Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 4 November 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2015-11.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'The Subcommittee recommended that lamivudine be funded for hepatitis B (HBV) reactivation prophylaxis for immunocompromised patients with a high priority. The Subcommittee recommended that &#39;immunocompromised&#39; be defined as &#39;any malignancy receiving rituximab and other immunosuppressant chemotherapies&#39;.', 'Formatted_Date__c': 'Nov 2015', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000Ar0tQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK5UAO'}, 'Id': 'a0P2P000005PAK5UAO', 'Event_Date__c': '2016-02-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar4gQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2017-11.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2017-11.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2016', 'fs': 'Oct 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Anti-Infective Subcommittee at meeting Thursday 13 October 2016.', 'fs': 'Clinical advice received from Anti-Infective Subcommittee at meeting Thursday 13 October 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK7UAO'}, 'Id': 'a0P2P000005PAK7UAO', 'Event_Date__c': '2016-10-13', 'Event_Description__c': 'Clinical advice received from Anti-Infective Subcommittee at meeting Thursday 13 October 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2017-11.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Oct 2016', 'Status_History__c': 'a132P000000ArCgQAK'}, 'change': None}]",May 2013,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2015', 'fs': 'Dec 2015', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK4UAO'}, 'Id': 'a0P2P000005PAK4UAO', 'Event_Date__c': '2015-12-04', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Dec 2015', 'Status_History__c': 'a132P000000Ar3OQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK6UAO'}, 'Id': 'a0P2P000005PAK6UAO', 'Event_Date__c': '2016-02-29', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar5zQAC'}, 'change': None}]",Dec 2015,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2016', 'fs': 'Nov 2016', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK8UAO'}, 'Id': 'a0P2P000005PAK8UAO', 'Event_Date__c': '2016-11-30', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2016', 'Status_History__c': 'a132P000000ArEQQA0'}, 'change': None}]",Nov 2016,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2017', 'fs': 'May 2017', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAK9UAO'}, 'Id': 'a0P2P000005PAK9UAO', 'Event_Date__c': '2017-05-12', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'May 2017', 'Status_History__c': 'a132P000000ArHoQAK'}, 'change': None}]",May 2017,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/news/consultation-2017-05-08-anti-infective/"" target=""_blank"">Consultation letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/news/consultation-2017-05-08-anti-infective/"" target=""_blank"">Consultation letter</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2017', 'fs': 'May 2017', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAKAUA4'}, 'Id': 'a0P2P000005PAKAUA4', 'Event_Date__c': '2017-05-26', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<a href=""https://www.pharmac.govt.nz/news/consultation-2017-05-08-anti-infective/"" target=""_blank"">Consultation letter</a>', 'Formatted_Date__c': 'May 2017', 'Status_History__c': 'a132P000000ArIJQA0'}, 'change': None}]",May 2017,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/news/notification-2017-06-12-anti-infective/"" target=""_blank"">Notification letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/news/notification-2017-06-12-anti-infective/"" target=""_blank"">Notification letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2017', 'fs': 'Jun 2017', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PAKBUA4'}, 'Id': 'a0P2P000005PAKBUA4', 'Event_Date__c': '2017-06-12', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<a href=""https://www.pharmac.govt.nz/news/notification-2017-06-12-anti-infective/"" target=""_blank"">Notification letter</a>', 'Formatted_Date__c': 'Jun 2017', 'Status_History__c': 'a132P000000ArIyQAK'}, 'change': None}]",Jun 2017,False,True
